Evoke Pharma (EVOK) Shares are Down -7.51%

Evoke Pharma (EVOK) : During the past 4 weeks, traders have been relatively bearish on Evoke Pharma (EVOK), hence the stock is down -78.42% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -7.56% relative to the S&P 500. The 4-week change in the price of the stock is -78.19% and the stock has fallen -7.51% in the past 1 week.

The stock has recorded a 20-day Moving Average of 14.33% and the 50-Day Moving Average is 54.67%. Evoke Pharma (NASDAQ:EVOK): stock turned positive on Friday. Though the stock opened at $2.21, the bulls momentum made the stock top out at $2.44 level for the day. The stock recorded a low of $2.18 and closed the trading day at $2.34, in the green by 4.93%. The total traded volume for the day was 1,017,459. The stock had closed at $2.23 in the previous days trading.


The company Insiders own 30.5% of Evoke Pharma shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -36.21% . Institutional Investors own 3.33% of Evoke Pharma shares. During last six month period, the net percent change held by insiders has seen a change of -42.39%. Also, Equity Analysts at the Noble Financial downgrades the rating on Evoke Pharma (NASDAQ:EVOK). The brokerage firm has issued a Hold rating on the shares. The shares were previously rated Buy. The rating by the firm was issued on July 19, 2016.

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Companys lead product candidate, EVK-001, is in late stage clinical testing. EVK-001 is a formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal, yielding a variety of symptoms.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.